Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LAVA-051
- Development stage
- Discontinued
- Lead developer
- LAVA Therapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
LAVA-051 is a humanized bispecific single-domain antibody (Gammabody) designed to engage and activate both Vγ9Vδ2 T cells and type 1 natural killer T (NKT) cells to target and kill CD1d-expressing tumor cells. The molecule consists of two single-domain antibodies linked by a short glycine-serine linker—one domain binds the Vδ2 chain of the Vγ9Vδ2 T cell receptor, while the other targets CD1d, a glycoprotein involved in antigen presentation on hematological malignancies such as chronic lymphocytic leukemia (CLL), multiple myeloma (MM), and acute myeloid leukemia (AML). Its mechanism leverages dual engagement for potent antitumor activity with a low risk of cytokine release syndrome. Developed using Lava Therapeutics' Gammabody platform, it was evaluated in phase 1/2a clinical trials for relapsed/refractory CLL, MM, and AML[3][6][7][8].
- Other names
- LAVA 051LAVA051LAVA-051Gammabody
02
Targets
TRDV2 (T cell receptor delta variable 2)iNKT TCR (Invariant natural killer T-cell receptor)CD1D (Tumor-associated macrophage/myeloid-derived suppressor cell CD1d complex)
Beyond the preview
Go deeper on LAVA-051.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LAVA-051.